SF3B1 and cancer: The use of OTS964, a selective inhibitor of CDK11, successfully suppresses the phosphorylation of SF3B1.[29] Alternative splicing and its regulatory processes are believed to be closely associated with cancer characteristics, and numerous splicing factors, such as SF3B1, have been demonstrated to be involved in tumorigenesis.[20, 30, 31, 32] However, the changes in these splicing factors during MZT and the regulatory role of alternative splicing in embryonic development have not been well elucidated.